论文部分内容阅读
目的探讨多发性骨髓瘤(MM)患者血清β2微球蛋白(β2-MG)和血清白蛋白(ALB)检测的临床意义。方法分别采用化学发光法和溴甲酚绿法检测38例MM患者血清β2-MG及ALB水平。结果Ⅰ期与Ⅱ、Ⅲ期比较,A组(血肌酐≤176.8μmol/L)与B组(血肌酐>176.8μmol/L)比较,以及完全缓解(CR)或部分缓解(PR)组化疗后与化疗前比较,患者的β2-MG后者均高于前者,差异有统计学意义(P均<0.01),无效组化疗前后β2-MG值差异无统计学意义(P>0.05);Ⅰ期患者的ALB水平高于Ⅱ、Ⅲ期(P均<0.05),但Ⅱ期与Ⅲ期,A组与B组患者的ALB水平相近(P均>0.05)。CR组或PR组患者化疗前的ALB水平低于化疗后,差异有统计学意义(P均<0.05)。无效组化疗前后ALB水平差异无统计学意义(P>0.05)。结论β2-MG和ALB水平可作为MM患者分期、预后、疗效判断的指标。
Objective To investigate the clinical significance of detecting β2 microglobulin (β2-MG) and serum albumin (ALB) in patients with multiple myeloma (MM). Methods Serum levels of β2-MG and ALB in 38 patients with MM were measured by chemiluminescence and bromocresol green assay respectively. Results Compared with those in stage Ⅱ and Ⅲ, the level of serum creatinine (176.6μmol / L) in group Ⅰ was significantly lower than that in group B (serum creatinine> 176.8μmol / L) and in complete remission (CR) Compared with those before chemotherapy, β2-MG in the latter group was significantly higher than those in the former group (all P <0.01), while there was no significant difference in β2-MG before and after chemotherapy (P> 0.05) The level of ALB in patients was higher than that in patients in stage Ⅱ and Ⅲ (all P <0.05), but in patients in stage Ⅱ and Ⅲ, ALB levels in patients in group A and B were similar (all P> 0.05). The level of ALB in patients with CR or PR before chemotherapy was lower than that after chemotherapy (P all <0.05). There was no significant difference in ALB levels between the two groups before and after chemotherapy (P> 0.05). Conclusion The levels of β2-MG and ALB can be used as indicators of staging, prognosis and curative effect in patients with MM.